FDA updates talazoparib and enzalutamide labeling, confirming survival benefits for HRR-mutated mCRPC, while excluding ...

FDA approvals and long-term study results, showcasing advancements in cancer treatments, and patient care strategies.

FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer, showing a ...

AbbVie Inc. (NYSE:ABBV) is one of the best stocks for a dividend stock portfolio. The company announced that the US FDA has ...

The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir) for ...

The approval comes more than three years after cabotegravir, which is offered by ViiV Healthcare under the name Apretude, was ...

When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...

The approval was based on two phase 1 crossover studies, which compared zanubrutinib tablets with the capsule formulation in healthy adult participants.

To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of ...